Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kiniksa Pharmaceuticals International, plc KNSA

Healthcare  —  Drug Manufacturers Specialty & Generic
75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Cash Flow Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio 59.77 49.13 51.56 79.24

+8 more quarters
P/S ratio 5.90 4.89 4.52 4.85
P/FCF ratio 27.12 22.42 22.42 28.49
P/Operating CF 105.12 73.39 56.79 86.15
P/B ratio 7.58 6.08 5.39 5.42
Price to Tangible BV 7.76 6.24 5.54 5.58
EV/Sales 5.27 4.27 3.91 4.26
EV/EBITDA 43.46 33.89 33.60 64.30
EV/Operating CF 23.98 19.39 19.18 24.78
EV/FCF 24.25 19.57 19.39 25.03
Quick Ratio 3.21 3.14 3.09 3.27
Current Ratio 3.90 3.79 3.79 3.85
Net Debt/EBITDA (19.01) (15.74) (20.46) (14.43)
Debt/Assets 0.00% 0.00% 0.00% 0.00%
Debt/Equity 0.00 0.00 0.00 0.00
Asset Turnover 1.08 1.06 1.01 0.94
Operating CF/Net income 1.86 2.22 3.80 1.83
Capex/Depreciation (1.40) (0.34) (1.36) (1.75)
Interest Coverage 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue 16.79% 12.82% 17.12% 13.36%
Selling, General and Administrative Expense of Revenue 26.22% 28.54% 28.09% 27.15%
Intangible Assets out of Total Assets 0.02 0.02 0.02 0.02
Share Based Compensation of Revenue 4.78% 4.69% 5.06% 5.61%
Graham Net Nets 0.09 0.10 0.11 0.10
Graham Number 14.25 13.21 11.73 8.89
Earnings Yield 1.67% 2.04% 1.94% 1.26%
Free Cash Flow Yield 3.69% 4.46% 4.46% 3.51%
Revenue per Share 3.14 2.80 2.72 2.42
Operating CF per Share 0.61 0.66 0.73 0.45
Capex per Share (0.01) 0.00 (0.01) (0.01)
Free Cash Flow per Share 0.60 0.65 0.72 0.44
Cash per Share 6.78 6.12 5.58 4.71
Shareholders Equity per Share 8.43 7.92 7.65 7.17
Interest Debt per Share 0.00 0.00 0.00 0.00
Book value per Share 8.43 7.92 7.65 7.17
Free Cash Flow 46.53 50.04 53.26 33.01
Working Capital 497.39 437.56 387.99 351.94
Capital Expenditures (0.66) (0.16) (0.63) (0.67)
Net Current Asset Value 426.67 374.58 331.15 298.58
EV/EBIT 44.24 34.50 34.27 66.81
Capex to Sales 0.00 0.00 0.00 0.00
Net Profit Margin 10.44% 10.54% 7.02% 10.19%
Price to Operating Income 49.49 39.52 39.64 76.04
Other line items
Average Receivables 27.70 31.64 28.66 38.32
Average Payables 10.68 13.19 2.03 7.24
Average Inventory 59.56 47.61 40.63 35.04
Average Assets 778.63 712.30 672.09 633.82
Average Common Equity 574.58 531.59 503.02 486.19

Fold the line items

Columns are period end dates